Patterns of Dose Escalation Amongst Patients with Ulcerative Colitis and Crohn's Disease Treated with Vedolizumab vs. Infliximab in the United States

被引：0
|
作者：
Khalid, Javaria Mona [1 ]
Raluy-Callado, Mireia [2 ]
Li, Qian [3 ]
Luo, Michelle [4 ]
Lasch, Karen [4 ]
机构：
[1] Takeda Dev Ctr Europe Ltd, London, England
[2] Evidera, London, England
[3] Evidera, Lexington, MA USA
[4] Takeda Pharmaceut USA Inc, Deerfield, IL USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2016年 / 111卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
700
引用
收藏
页码：S316 / S317
页数：2
相关论文
共 50 条
  • [1] Hospitalizations and Characteristics of Patients with Ulcerative Colitis and Crohn's Disease Treated with Vedolizumab in the United States
    Reynolds, Matthew
    Raluy-Callado, Mireia
    O'Hara, Don
    Alam, Naufil
    Smyth, Michael
    Khalid, Mona
    INFLAMMATORY BOWEL DISEASES, 2016, 22 : S17 - S17
  • [2] Hospitalizations and Treatment Discontinuation among Patients with Ulcerative Colitis and Crohn's Disease Treated with Vedolizumab Compared with Infliximab
    Khalid, Javaria Mona
    Raluy-Callado, Mireia
    Alam, Naufi L.
    Wang, Rosa
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S317 - S317
  • [3] EFFECTIVENESS AND DURABILITY OF USTEKINUMAB DOSE ESCALATION IN CROHN'S VS ULCERATIVE COLITIS PATIENTS
    Khan, Muhammad Umair
    Lee, Bee
    Lee, Sujin
    Hawker, Peter
    GUT, 2023, 72 (SUPPL_2) : A119 - A119
  • [4] MUCOSAL HEALING IN PATIENTS TREATED WITH INFLIXIMAB IN CROHN'S DISEASE AND ULCERATIVE COLITIS
    Boyd, J.
    Lee, L.
    Lanzon-Miller, S.
    GUT, 2013, 62
  • [5] Reductions in Corticosteroid Use in Patients with Ulcerative Colitis or Crohn's Disease Treated with Vedolizumab
    Sands, Bruce
    Hanauer, Stephen
    Colombel, Jean-Frederic
    Danese, Silvio
    Abreu, Maria
    Ahuja, Vineet
    Ponich, Terry
    Hilmi, Ida
    Sankoh, Serap
    Smyth, Michael
    Abhyankar, Brihad
    Fox, Irving
    Feagan, Brian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S503 - S503
  • [6] A comparative efficacy and safety analysis of subcutaneous infliximab and vedolizumab in patients with Crohn's Disease and Ulcerative Colitis
    Peyrin-Biroulet, L.
    Arkkila, P.
    Armuzzi, A.
    Atreya, R.
    Danese, S.
    Ferrante, M.
    Guardiola, J.
    Jahnsen, J.
    Louis, E.
    Lukas, M.
    Reinisch, W.
    Roblin, X.
    Smith, P. J.
    Kwon, T. S.
    Kim, J. Y.
    Yoon, S. W.
    Kim, D. H.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I1116 - I117
  • [7] Infliximab dose intensification in patients with crohn's disease and ulcerative colitis: associated costs
    Taxonera, Carlos
    Olivares, David
    Mendoza, Juanl
    Caas, Mercedes
    Diaz-Rubio, Manuel
    Rey, Enrique
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 812 - 813
  • [8] Need for infliximab dose intensification in Crohn's disease and ulcerative colitis
    Taxonera, Carlos
    Olivares, David
    Mendoza, Juan L.
    Diaz-Rubio, Manuel
    Rey, Enrique
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (27) : 9170 - 9177
  • [9] Need for infliximab dose intensification in Crohn's disease and ulcerative colitis
    Carlos Taxonera
    David Olivares
    Juan L Mendoza
    Manuel Díaz-Rubio
    Enrique Rey
    World Journal of Gastroenterology, 2014, 20 (27) : 9170 - 9177
  • [10] Efficacy, Safety, and Pharmacokinetics of Infliximab Dose Escalation in Pediatric Patients With Crohn's Disease or Ulcerative Colitis: An Analysis of the DEVELOP Registry
    Dubinsky, Marla C.
    Markowitz, James
    Busse, Christopher
    Koletzko, Sibylle
    Winter, Harland
    Baldassano, Robert
    Colletti, Richard
    Kugathasan, Subra
    Ruemmele, Frank
    Griffiths, Anne
    Gasink, Christopher
    Adedokun, Omoniyi
    Izanec, James L.
    Gao, Long-Long
    Ma, Tony
    Ott, Elyssa
    Hyams, Jeffrey
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S592 - S593
12345